PRGO vs HCM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PRGO · Perrigo$15.85 ▲ 0.89%
HCM · Hutchmed (China)$15.16 ▲ 6.76%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PRGO +19.1%
- HCM +0.5%
Head to head
| Metric | PRGO | HCM |
|---|---|---|
| Price | $15.85 | $15.16 |
| Change today | ▲ 0.89% | ▲ 6.76% |
| Market cap | $2.20B | $2.64B |
| Return, 3 months | +28.0% | +20.8% |
| Return, year to date | +21.9% | +13.7% |
| Return, 1 year | +17.5% | +1.4% |
| P/E (TTM) | – | 189.5 |
| P/B | 0.9 | 2.1 |
| P/E percentile vs own 5y | 87th | 97th |
| Dividend yield | 7.32% | – |
| Revenue growth (YoY, latest qtr) | -3.2% | +37.3% |
| Net profit growth (YoY) | +985.7% | -81.3% |
| Gross margin | 33.3% | 41.6% |
| Operating margin | 6.0% | -5.7% |
| Net margin | -41.9% | 3.3% |
| Return on equity | -49.6% | 1.4% |
| Analyst target vs. price | +19.9% | +20.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 56 | 63 |
| 30-day volatility | 35.2% | 44.6% |
| Max drawdown, 1 year | -56.9% | -37.8% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HCM is the largest of the group by market value.
- PRGO has returned the most over the past year.
- HCM is growing revenue fastest.
- HCM keeps the most profit per dollar of sales.
- PRGO has been the calmest stock over the last 30 days.